76%

of patients are not satisfied with weight loss solutions they’ve tried|footnote-311|

Elipse is a game-changing weight loss device that matches your patients' needs and helps them meet their weight loss expectations.|footnote-311|

A fast and efficient procedure

The Elipse Balloon is swallowed during a standard 20-minute consultation.|footnote-89| It passes out naturally approximately 16 weeks later.|asterisk-293|

 

Elipse is a breakthrough in simplicity: there is no surgery, no endoscopy|asterisk-293| and no anaesthesia required. The programme offers demonstrated efficacy alongside the convenience of a walk-in placement. Your patient enjoys the privacy of fast and effective outpatient treatment at your clinic. This personalised approach means no one in their immediate circle needs to know they have had the placement.         

Effective results

After approximately 16 weeks of Elipse therapy, patients lose an average of 10 to 15kgs (1.57 to 2.36 stone).|footnote-90| |footnote-302| |footnote-296| |footnote-297| |footnote-295| |footnote-298| |footnote-299| |footnote-300| |footnote-301| |footnote-303|

 

When coupled with a 16-week intensive lifestyle modification, Elipse leads to significant weight loss compared to lifestyle modification alone.
However, a temporary balloon does not mean temporary weight loss. One study showed that 72% of average weight loss can be sustained after 12 months.|footnote-90|

Multidisciplinary support

Patients receive medical and nutritional support for the duration of the programme, along with a smartphone app and a connected scale to track progress.

 

Elipse is more than "just a balloon". It’s a fully supported weight-loss programme that is tailored to individual needs. It provides your patients with the nutritional support and exercise guidance they need to make life-changing habits to kick-start their weight-loss journey.|asterisk-307|

Elipse Balloon is the world’s first and only weight loss gastric balloon requiring no surgery, no endoscopy|asterisk-293|, or anaesthesia.
A revolutionary material

A revolutionary material

The balloon material is flexible enough to fold into a capsule and safely pass through the GI tract, yet durable enough to spend 16 weeks in the stomach|footnote-90| |footnote-296| |footnote-314|

swallowable gastric balloon

Swallowing the balloon

The capsule is swallowed along with a thin delivery catheter that facilitates filling. A study shows 99.9% of patients are able to swallow the device, with only 32% requiring stylet assistance.|footnote-302|

Elipse balloon fill valve

The fill valve

The fill valve is made from thin film that seals shut after the delivery catheter is removed.

Elipse balloon release valve

The release valve

This is made from a thin film and a degradable filament. The release valve progressively weakens and then opens at a pre-determined time to allow the balloon to empty.|footnote-90| |footnote-296| |footnote-314| The empty balloon then passes through the GI tract naturally or may be vomited in a very small number of patients. Vomiting of the balloon has not been associated with any reported adverse events to date.

An excellent safety profile with proven efficacy

The largest Elipse data collection to date featured|footnote-302|

  • 1623 consecutive patients

  • 19 centres

  • 7 countries

weight loss

At 4 months

Total Body Weight Loss was
13.6% ±5,7%

Mean Weight Loss
12.9kgs ±6.5kgs

BMI reduction
4.9kg/m² ±3.3kg/m2

metabolic improvement

All metabolic parameters improved; triglycerides, LDL cholesterol and level of blood sugar (measured in a subset of 407 patients)

swallowable gastric balloon

99.9%

of patients were able to swallow the device

Discover the Allurion Master Classes

Watch our experts discuss clinical updates, international market research and so on..

Go
The best Elipse experience for your patients

Support from day 1

  • Place your first 10 balloons with the support of the Allurion team
  • Use in-clinic communication tools
  • Get support to help you create a tailored, multidisciplinary Elipse programme

Benefit from Allurion’s expertise

  • Clinical expertise
  • Research
  • Allurion Academy
  • Staff training
  • Online support
  • Customer care manager

Improve patient engagement and follow-up

  • Long-term programme
  • Connected smart scale
  • Allurion app

Publications & clinical studies

The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis

, Obesity Surgery

 

Kornpong Vantanasiri, Reem Matar, Azizullah Beran & Veeravich Jaruvongvanich

The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients

, Obesity Surgery

R. Ienca, Mohammed Al Jarallah, Adelardo Caballero, Cristiano Giardiello, Michele Rosa, Sébastien Kolmer, Hugues Sebbag, Julie Hansoulle, Giovanni Quartararo, Sophie Al Samman Zouaghi, Girish Juneja, Sébastien Murcia, Roman Turro, Alberto Pagan, Faruq Badiuddin, Jérôme Dargent, Pierre Urbain, Stefan Paveliu, Rita Schiano di Cola, Corrado Selvaggio & Mohammed Al Kuwari

The Safety and Efficacy of Procedureless Gastric Balloon: a Study Examining the Effect of Elipse Intragastric Balloon Safety, Short and Medium Term Effects on Weight Loss with 1-Year Follow-Up Post-removal.

, Obesity Surgery

Jamal MH, Almutairi R, Elabd R, AlSabah SK, Alqattan H, Altaweel T.

The safety and efficacy of the procedureless intragastric balloon

, Surgery for Obesity and Related Diseases

Salman Alsabah, M.B.A., F.R.C.S.C., F.A.C.S 
Eliana Al Haddad, M.D.
Shehab Ekrouf, F.R.C.S.
Ahmad Almulla, F.R.C.S.
Saud Al-Subaie, F.R.C.S.
Mubarak Al Kendari, F.R.C.S

A prospective pilot study of the efficacy and safety of Elipse intragastric balloon: A single-center, single-surgeon experience.

, International Journal of Surgery, Vol. 48

Al-Subaie S., Khalifa S., Buhaimed W., Al-Rashidi S.

Safety and Efficacy of a New Swallowable Intragastric Balloon Not Needing Endoscopy: Early Italian Experience.

, Obesity Surgery

Genco, Ernesti, Ienca, Casella, Mariani, Francomano, Soricelli, Lorenzo, Monti

The Elipse Balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia or endoscopy: a pilot study with 12-month outcomes

, Surgery for Obesity and related Diseases, Vol. 13

Ioannis Raftopoulos, M.D., Ph.D., F.A.C.S., F.A.S.M.B.S., Andreas Giannakou, M.D.

Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study

, Endoscopy, Vol. 49

Evzen Machytka, Shantanu Gaur, Ram Chuttani, Martina Bojkova, Tomas Kupka, Marek Buzga, Andreas Giannakou, Kandiliotis Ioannis, Elisabeth Mathus-Vliegen, Samuel Levy, Ioannis Raftopoulos

Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study

, Obesity Surgery, Vol. 26

Evzen Machytka, Ram Chuttani, Martina Bojkova, Tomas Kupka, Marek Buzga, Kathryn Stecco, Samuel Levy & Shantanu Gaur

How can we help?

We’re here to answer any questions you may have. 


In case of a medical emergency or other medical questions, please contact your Elipse clinic or local healthcare provider.

You are

|asterisk-293|In rare cases, the Elipse Balloon may require endoscopic or surgical intervention for removal. In rare cases, the empty balloon may be vomited instead of passing through the GI tract.

|asterisk-307|The Elipse Balloon must be used in conjunction with a supervised nutrition and behavior modification programme. Allurion advises a 6-month follow-up programme. Its duration is defined by the physician and may vary depending on the physician and patient profile.

|footnote-89|Clinical Trial Reports: DAA069 and DAA105

|footnote-90|Jamal et al. Obes Surg. 2019 Apr;29(4):1236-1241.

|footnote-295|Raftopoulos and Giannakou. SOARD. 2017 Jul;13(7):1174-1182.

|footnote-296|Al Sabah, S., et al. SOARD. 2018, 14(3), 311-317.

|footnote-297|Machytka E et al. Endoscopy. 2017 Feb;49(2):154-160.

|footnote-298|Genco et al. Obes Surg 2017,DOI 10.1007/s11695-017-2877-1

|footnote-299|Al-Subaie S et al. Int J Surg. 2017 Dec;48:16-22.

|footnote-300|Ienca et al. Submitted to SOARD. Abstract A278, presented at Obesity Week, 2018, Nashville, USA

|footnote-301|Genco et al. Abstract A185. Oral Presentation at Obesity Week, 2018, Nashville, USA

|footnote-302|Ienca et al. Abstract 237, presented at IFSO 2019, Madrid, Spain

|footnote-303|Raftopoulos et al. Abstract 1978. Presented at ACS 2019, San Francisco, United States

|footnote-311|Allurion consumer market research; 9,800 respondents; 8 geographies; Oct 2018

|footnote-314|Clinical Reports: DAA018, DAA069 and DAA105